Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FK506 in solid organ transplantation

J J Fung1, T E Starzl

  • 1Division of Transplantation Surgery, Pittsburgh Transplantation Institute, PA 15213, USA.

Therapeutic Drug Monitoring
|December 1, 1995
PubMed
Summary

FK506 (Prograf) effectively reverses organ transplant rejection, improving patient and graft survival in liver, kidney, heart, and lung transplants. This immunosuppressant shows comparable or superior outcomes to cyclosporine with fewer side effects like hypertension.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Il-12 antagonism enhances apoptotic death of T cells within hepatic allografts from Flt3 ligand-treated donors and promotes graft acceptance.

Journal of immunology (Baltimore, Md. : 1950)·2001
Same author

Ischemic preconditioning: application in clinical liver transplantation.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2001
Same author

Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs.

The American journal of pathology·2001
Same author

Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus.

Journal of clinical pharmacology·2001
Same author

Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts.

Transplantation proceedings·2001
Same author

Phenotype and allostimulatory function of dendritic cells treated with antisense oligodeoxyribonucleotides targeting CD80 or CD86 mRNA.

Transplantation proceedings·2001

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Pharmacology

Background:

  • FK506 (Prograf) is an approved immunosuppressive agent for solid organ transplants.
  • Initial use targeted refractory liver allograft rejection, demonstrating significant efficacy.

Purpose of the Study:

  • To evaluate the efficacy of FK506 in reversing established organ transplant rejection.
  • To compare FK506 with cyclosporine in primary liver transplantation.
  • To assess FK506's effectiveness in various solid organ transplantations.

Main Methods:

  • Clinical trials comparing FK506 to cyclosporine in primary liver transplantation.
  • Analysis of patient and graft survival rates.
  • Review of FK506 use in rescue therapy for kidney allografts.

Related Experiment Videos

  • Assessment of FK506 in primary heart and lung transplantation.

    • Main Results:

    • FK506 reversed ongoing rejection in 50-70% of liver transplant patients.
    • Long-term follow-up showed 75% patient survival and 65% graft survival at 3 years post-conversion.
    • Randomized trials indicated greater freedom from rejection with FK506 versus cyclosporine.
    • FK506 demonstrated similar or better patient and graft survival compared to cyclosporine.
    • Reduced incidence of hypertension and steroid use observed in FK506 patients.
    • Positive outcomes reported for FK506 in kidney, heart, and lung transplantation.

    Conclusions:

    • FK506 is an effective immunosuppressant for solid organ transplantation.
    • FK506 demonstrates significant efficacy in reversing and preventing transplant rejection.
    • While FK506 shares some side effects with cyclosporine, it offers distinct advantages.